Gene Bio Tech Co., Ltd.

VANCOUVER, BC and BINH DINH, Vietnam, March 17, 2025 /PRNewswire/ - Gene Bio Medical (GBM), a leading Canadian biotechnology company specializing in molecular diagnostics, has signed a Memorandum of Understanding (MOU) with Bình Định Pharmaceutical - Medical Equipment Joint Stock Company (BIDIPHAR) to establish a large-scale production facility in Bình Định, Vietnam. This strategic joint venture aims to manufacture high-quality diagnostic test kits using Canadian technology to serve Vietnam, Southeast Asia, the Middle East, and North America. Continue Reading Scene of the MoU Signing Ceremony. Photo: L.A. (CNW Group/Gene Bio Medical) The announcement was made during a high-profile meeting between the Bình Định People's Committee, representatives from the Consulate General of Canada in Ho Chi Minh City, the British Columbia Office in Vietnam, and key executives from Gene Bio Medical and BIDIPHAR. Investment and Market Expansion GBM, headquartered in British Columbia, Canada, is recognized for its breakthrough innovations in molecular diagnostics and AI-driven healthcare solutions. During the COVID-19 pandemic, GBM played a critical role in global public health, delivering over 48 million high-quality SARS-CoV-2 rapid test kits to the Government of Canada. With an established distribution network in 4,900 independent pharmacies and hospitals across Canada, GBM's respiratory diagnostic product line is set to receive FDA approval in 2025. The company's proprietary RNA and DNA biomarker detection technologies offer femtomolar sensitivity, providing accuracy on par with or exceeding PCR testing. By integrating AI-driven diagnostics, GBM enhances speed, precision, and scalability, reinforcing its position as a global leader in molecular diagnostics. GBM's Business Mission to Vietnam and Partnership with BIDIPHAR In late March 2024, Gene Bio Medical participated in a Canadian trade mission delegation led by Canada's Minister of Trade, Mary Ng, on visits to Hanoi and Ho Chi Minh City. During this mission, the Consulate General of Canada facilitated a B2B meeting to introduce BIDIPHAR to Gene Bio Medical. In November 2024, the Women trade mission led by Asia Pacific Foundation of Canada, Voice president Christine Nakamura and Director A.W Lee. visited Vietnam again and met with BIDIPHAR's CEO Ms. Phạm Thị Thanh Hương in Ho Chi Minh City, reaching a preliminary agreement. At the meeting in Bình Định, representatives from the provincial government and various departments introduced Bình Định's economic and social landscape, investment directions, and priority sectors. The discussion also covered GBM's investment plans, the joint venture with BIDIPHAR, and investment incentives offered by the province. Strategic Partnership and Vision The BIDIPHAR-GBM joint venture represents a $10-20 million USD investment aimed at establishing a state-of-the-art manufacturing facility in Bình Định. This collaboration is a testament to GBM's commitment to global expansion and pandemic preparedness, positioning the company as a key player in next-generation diagnostics. Key objectives of the joint venture: Establish a cutting-edge production facility in Bình Định, Vietnam. Serve the Vietnamese market and expand into Southeast Asia, the Middle East, and North America. Advance pandemic preparedness with scalable diagnostic solutions. Achieve a U.S. NASDAQ listing and Vietnam Stock Exchange listing within five years. Vietnam's Pro-Business Investment Climate Bình Định Province has emerged as a premier investment destination in Vietnam, offering strategic incentives for foreign investors. The Vietnamese government and Bình Định People's Committee are providing attractive investment benefits, including: Corporate income tax incentives: 10% tax rate for the first 15 years. Tax exemption for the first four years. 50% tax reduction for the next nine years. Import tax exemptions: Five-year exemption on imported raw materials and semi-finished products unavailable domestically. Land and rental incentives: Discounts and exemptions based on industry classification and investment scale. With Bình Định's robust infrastructure and investor-friendly policies, the BIDIPHAR-GBM joint venture is poised for long-term success, accelerating biotechnology advancements in Vietnam and beyond. Quotes from Key Leaders Jessica Hu, CEO & Founder of Gene Bio Medical, stated: "Vietnam's growing healthcare market and strategic location make it an ideal hub for our expansion. Our partnership with BIDIPHAR will leverage Canadian technology to provide affordable, high-quality diagnostic solutions across global markets. This joint venture aligns with GBM's mission to enhance global health security through innovation and accessibility." Lâm Hải Giang, Vice Chairman of Bình Định People's Committee, commented: "We welcome Gene Bio Medical's investment in Bình Định's biotechnology sector, a key pillar of our economic strategy. The province remains committed to supporting international investors by providing world-class infrastructure and regulatory incentives." About Gene Bio Medical (GBM) Gene Bio Medical (GBM) is a fully integrated diagnostics company specializing in molecular diagnostics and AI-driven healthcare solutions. Headquartered in British Columbia, Canada, GBM oversees the entire diagnostics value chain, from R&D and manufacturing to global distribution. The company is committed to delivering high-precision, cost-effective diagnostic solutions to address global health challenges, including respiratory diseases, infectious outbreaks, and chronic illnesses. Facebook | Instagram | X | LinkedIn About BIDIPHAR Bình Định Pharmaceutical - Medical Equipment Joint Stock Company (BIDIPHAR) is a leading Vietnamese pharmaceutical company specializing in medical equipment and diagnostic products. With decades of expertise, BIDIPHAR is recognized for its commitment to quality, innovation, and healthcare advancement in Vietnam and international markets. Related Articles For further information: Website: Email: [email protected] SOURCE Gene Bio Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VANCOUVER, BC, March 6, 2025 /PRNewswire/ - GBM Health Holding, a global leader in integrated healthcare innovation, is proud to announce that its subsidiaries Gene Biotechnology Enterprises Ltd(Operating business as: "Gene Bio Medical") and Geno10X Bioscience Inc have been awarded a combined $1.5 million CAD in funding from Innovate BC. The grants, part of Innovate BC's Ignite Program, will accelerate the development of cutting-edge clean technology and life sciences solutions poised to transform healthcare and environmental sustainability. Driving Innovation Across Precision Medicine and Biotech The funding supports two pioneering projects: Gene Bio Medical – Advancing a next-generation AI-powered diagnostic platform for early detection of chronic diseases, leveraging proprietary biomarker algorithms to improve patient outcomes while reducing healthcare costs. Geno10X Bioscience Inc – Scaling its sustainable bioreactor technology, which uses synthetic biology to produce high-value pharmaceuticals with 80% lower carbon emissions compared to traditional methods. "This recognition from Innovate BC underscores our commitment to solving critical challenges at the intersection of human health and planetary sustainability," said Jessica Hu, CEO of GBM Health Holding. "By combining Gene Bio Medical's precision diagnostics with Geno10X's green biomanufacturing, we're not only pushing scientific boundaries but also creating scalable solutions that benefit both patients and the environment." Strategic Impact and Market Potential Gene Bio Medical's project aligns with British Columbia's growing leadership in digital health, with potential applications across North America and Asia-Pacific markets. Meanwhile, Geno10X's bioreactor innovation addresses urgent global demand for decarbonized drug production, a sector projected to reach $30 billion by 2030. Both initiatives are expected to generate high-value jobs in BC and strengthen partnerships with academic institutions, including the University of British Columbia. About GBM Health Holding GBM Health Holding is a Vancouver-based conglomerate driving innovation across precision medicine, genomics, and sustainable biotechnology. Through subsidiaries like Gene Bio Medical and Geno10X, the company bridges advanced R&D with commercial solutions that prioritize health equity and environmental stewardship. Learn more at: . SOURCE Gene Bio Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TORONTO, June 19, 2023 /PRNewswire/ - Gene Biotechnology Enterprises Ltd., also known as Gene Bio Medical, is excited to announce its strategic partnership with the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI³). This collaboration forms part of an ambitious initiative titled "Pandemic preparedness engaging primary care and emergency departments (PREPARED)." The project is led by Dr. Andrew Pinto, Founder and Director of the Upstream Lab and Associate Professor at the University of Toronto. Gene Bio Medical has been invited by Dr. Pinto to partner on the commercialization and manufacturing aspects of the project, which aims to engage primary care and emergency departments across six provinces in Canada. With its four-pronged objective - integrating point-of-care tests, improving surveillance, linking patients to trials, and accelerating the creation of diagnostics - the project marks a significant step towards improving pandemic preparedness. HI3, one of the five hubs evaluating R&D projects for the Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF), is a coalition of academic, hospital, research networks, industry, government, not-for-profit, and community partners, including the University of Toronto. Its mission is to collaboratively bolster Canada's biomanufacturing capacity to ensure a fast and coordinated response to future pandemics and infectious health threats. The partnership highlights the unique value that Gene Bio Medical brings as a commercialization and manufacturing partner. With its significant contribution to the fourth objective of the project, Gene Bio Medical will accelerate the creation and deployment of innovative diagnostic solutions. This partnership marks the third of its kind for Gene Bio Medical within the CBRF/BRIF program. The company continues to be sought out by leading R&D organizations, solidifying its reputation as a trusted partner for the commercialization and manufacturing of innovative medical solutions. Jessica Hu, CEO of Gene Bio Medical, commented, "We're proud to collaborate with HI³ and contribute to the PREPARED project. Our continued involvement in initiatives under the CBRF/BRIF program demonstrates our commitment to advancing global health solutions." About Gene Bio Medical: Gene Biotechnology Enterprises Ltd., operating as Gene Bio Medical, is a leader in the field of biomedical commercialization and manufacturing. The company represents a "Made in Canada" opportunity for the manufacture of innovative medical products. As the primary commercial and biomanufacturing partner, Gene Bio Medical takes the lead in the pandemic preparedness for Canadian people. Their involvement in major research projects underlines their commitment to the development of ground breaking technologies and products that can positively impact global health. Gene Bio Medical is a biotechnology innovator with demonstrated commercialization capability in the Life Sciences industry. As a fast-growing biomedical company with its own manufacturing lines, Gene Bio Medical collaborates with worldwide partners and universities to provide global healthcare professionals and customers with the latest leading-edge technologies that help improve health and quality of life, revolutionizing healthcare. The company has a mission is to provide the world with the best possible diagnostic solutions to enable them to diagnose and prevent potential health issues. Gene Bio Medical strives to be the market leader in providing high-quality, evidence-based, cost-effective, and reliable products that are accessible to everyone. SOURCE Gene Bio Medical